Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Edison Investment Research
$10.00
Provider: GlobalData
$125.00
Provider: Crystal Research Associates
$817.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Amarantus Bioscience Holdings Inc announcs positive clinical data for Eltoprazine in Phase 2a clinical study Adult Attention Deficit Hyperactivity Disorder


Tuesday, 4 Feb 2014 09:06am EST 

Amarantus Bioscience Holdings Inc:Says positive clinical data for Eltoprazine in a Phase 2a clinical study Adult Attention Deficit Hyperactivity Disorder.Says the results from the study demonstrated statistically improvements of both doses of 5mg and 10mg vs.Says placebo in a range of ADHD clinical measures.Says following a thorough statistical review of the data announced by Psychogenics in 2008 by an independent clinical CRO retained for due diligence purposes, an updated study report was submitted in the Investigator's Brochure in 2010 that was better than originally reported.Says the ADHD market is valued at over $3.5 bln dollars, with about 35 mln prescriptions written annually. 

Company Quote